55 results about "Tetracaine" patented technology

The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine.

A topical liquid aerosol formulation for accurate metered dose delivery has been developed which includes a concentrate comprising a local anesthetic in a non-alcohol solvent and a hydrofluorocarbon (HFC) propellant. In the preferred embodiment, the concentration of the non-alcohol solvent in the concentrate is between about 75% and 85% by weight of the formulation. In the most preferred embodiment, the non-alcohol solvent is a water-soluble polyol such as ethylene glycol, propylene glycol, glycerol, diethylene glycol, dipropylene glycol, oligoalkylene glycols, liquid polyalkylene glycols, or combinations thereof. In one embodiment, the concentration of the local anesthetic in the concentrate is between about 15% and 25% by weight. In the preferred embodiment, the hydrofluorocarbon propellant is 1,1,1,2-tetrafluoroethane 1,1,1,2,3,3,3-heptafluoropropane or combinations thereof, in a concentration between about 35% and 65% by weight of the final formulation, more preferably between about 45% and 55% by weight of the final formulation. A particularly preferred formulation includes benzocaine, tetracaine, and butylaminobenzoate, wherein the concentration of benzocaine in the concentrate is 14% by weight, the concentration of tetracaine in the concentrate is 2% by weight, and the concentration of butylaminobenzoate in the concentrate is 2% by weight. It has been found that the formulation is more stable in the substantial absence of oxygen. The formulation is preferably administered using a metered dose device for release of a controlled amount of the local anesthetic.

A composition for anesthetizing oral or buccal tissues, especially periodontal pockets, is provided. The composition has a high concentration of topical anesthetic carried in a non-aqueous liquid vehicle containing a gelling agent. The anesthetics are optionally stabilized in the solution by ion-exchange complexation. The composition can anesthetize the gingivae for an extended period, such as 30 minutes or longer. Preferred anesthetics include tetracaine, benzocaine, butamben, and mixtures of these.

The invention relates to a method for preparing tetracaine, which comprises the following steps: dissolving para aminobenzoic acid and n-butanal in absolute methanol, preserving temperature and mixing; then concentrating to remove methanol to obtain 4-(n-butene amino) benzoic acid; adding the 4-(n-butene amino) benzoic acid, water and sodium hydroxide into a high pressure reaction kettle; then adding palladium carbon (10%), and introducing hydrogen to reduce so as to obtain 4-(n-butyl amino) benzoic acid; adding the 4-(n-butyl amino) benzoic acid into another reaction flask, adding toluene and then adding N,N-dimethylethanolamine; refluxing and dividing water; and then purifying and drying to obtain tetracaine. The method provided by the invention has the advantages of low cost of raw materials, high yield and high purity and the like.

The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations.

A topical anesthetic for dental procedures is provided containing about 3 wt % to 10 wt % tetracaine in a vehicle suitable for administration to the oral mucosa. The vehicle for transporting the tetracaine includes a water soluble mucoadhesive or a combination of mucoadhesives such as a high molecular weight poly(ethylene oxide) homopolymer and a cellulose polymer. The vehicle may additionally include a penetration enhancer such as propylene glycol. The tetracaine is ground into a powder and is suspended in a plasticized hydrocarbon gel which completes the vehicle.

The invention discloses a medicine composition with the functions of narcotizing in an operation and alleviating pain after the operation. The medicine composition comprises tetracaine, bupivacaine, mastic, rhizoma cyperi, girald daphne bark, white peony root and menthol. The medicine composition is added with conventional auxiliary materials in pharmacy according to a conventional process to prepare a clinically acceptable medicament form. The medicine composition is a medicine for injecting and narcotizing in the operation and alleviating pain in a long acting way after the operation and is already applied to clinic successfully throughout the years. The medicine composition can enable the surgical field to be clear, can also avoid pain, sagging distention, frequent defecation and uroschesis caused by the operation, can loosen the anal canal fully and is convenient for the surgical operation.

The invention relates to a sustained-release analgesic drug, which is microsphere of a topical anesthesia agent. The topical anesthesia agent comprises lidocaine, tetracaine, bupivacaine, oxybuprocaine and procaine. The sustained-release microsphere provided by the invention can be prepared into a sterile microsphere injection, a powder, a spray, a tablet, a capsule, a lozenge, a soft capsule, a pill, a syrup, an external ointment, an emulsion, a bandage, a binder and a gauze. The sustained-release microsphere can be prepared by a multiple double emulsion method, a non-aqueous method, a low temperature spray extraction method or a phase coacervation method. The sustained-release analgesic drug provided by the invention can be used for pain killing of skin wounds with small area, such as cuts, abrasions and burns, and operation wounds.

The present invention relates to an eye drops for preventing and curing electric ophthalmitis with high cure rate and obvious therapeutic effect. Its composition contains dicaine hydrochloride 0.5g, sodium chloride 0.82g, 0.1% adrenaline injection solution 5 ml and distilled water adding to 100ml.

The present disclosure is drawn to methods for treating various types of pain, including pain associated nerve entrapment, neuroma, headaches, connective tissue, arthritis, injury, and/or overuse. Specifically, the method includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic system on the skin surface for an application period of at least 30 minutes. Following the application period the analgesic system can be removed and the subject being treated continues to experience reduction of pain for a period of 2 to 10, or even 4 to 12 hours after removal of the analgesic system. The analgesic system applied to the skin surface can include a heating component and a local anesthetic formulation.

A topical anesthetic is provided containing about 3 wt % to 10 wt % tetracaine in a vehicle suitable for administration to the mucosa. The vehicle for transporting the tetracaine includes a water soluble mucoadhesive or a combination of mucoadhesives such as a high molecular weight poly(ethylene oxide) homopolymer and a cellulose polymer. The vehicle also includes propylene glycol. The tetracaine is ground into a powder and is suspended in a plasticized hydrocarbon gel which completes the vehicle.

A topical anesthetic composition comprising benzocaine, pharmaceutically acceptable salt thereof, amide thereof and/or ester thereof; tetracaine and/or pharmaceutically acceptable salt thereof; ethanol; polyethylene glycol; propylene glycol; water; and benzyl alcohol is provided. Also provided is method for dispensing the above topical anesthetic composition to a desired site such by spraying the topical anesthetic from a pump actuated metered dose spray device. The topical anesthetic composition can also be administered subgingivally with a syringe and applicator tip. A product comprising the above topical anesthetic spray composition contained in a pump actuated metered dose spray device.

The invention discloses a facial mask for surface surgical anesthesia. A main body material of the facial mask is facial mask paper or facial mask fabric, wherein the main body material is soaked withChinese herbal medicine extract and local anesthetics; and anesthetic components consist of frankincense extract, myrrh extract, Sichuan pepper extract, chamomile extract, sweet-scented osmanthus extract, licorice root extract, borneol, mint, lidocaine and tetracaine. The facial mask for the surface surgical anesthesia combines the traditional Chinese medicines and the western medicines, the amounts of the lidocaine and the tetracaine as well as toxic reaction produced thereby can be apparently reduced, and the facial mask also has a sterilizing effect, an inflammation eliminating effect anda swelling diminishing effect; and in addition, the facial mask can realize the local skin anesthesia in a short time, and has the characteristics of rapidness in effectiveness, strong and lasting action, high permeation force, less unfavorable reaction and the like.

The invention discloses a drug for preventing or treating oral diseases. According to the drug, gelatin sponge, rhizoma cibotii or chitosan serves as a carrier, clove oil, iodoform, calcium hydroxideand Peru balsam serve as active ingredients, and an appropriate amount of local anesthetics are added, wherein the local anesthetics are one of lidocaine, tetracaine and loxoprofen. The drug has various pharmacological effects such as anti-inflammation, pain relief, disinfection, antisepsis, hemostasis, promotion of tissue regeneration, prevention of secondary infections, and promotion of periodontal tissue regeneration. Moreover, the drug is convenient to take and easy to remove and has high permeability; the pain of patient's oral lesions can be quickly relieved, external liquid is effectively prevented from entering cavities, the barrier function of the drug can prevent double infections, the temperatures of the lesions are reduced, and dysfunctions such as local swelling and pain of mucous membranes are quickly eliminated, so that the drug is beneficial to repair of the oral mucous membranes.

The invention discloses a tetracaine ethosome prepared from the following raw materials in percentage by weight: 0.3-5% of tetracaine, 1.0-5.0% of egg yolk lecithin, 30-80% of short chain alcohol and 14-68% of water. The tetracaine ethosome is a novel percutaneous agent carrier, has a novel mostly spherical or nearly spherical multicellular vesicle structure, has the characteristics of more stable thermodynamics, smaller particle diameter, high encapsulation rate up to 82.36%, faster and stronger percutaneous performance, good skin tolerance, lower dosage and the like, reduces the occurrence rate of adverse response, and improves the safety.

The invention discloses an external medicine for treating cancer pain and a preparation method thereof. The external medicine for treating cancer pain is composed of the following raw material medicines: 20-50 g of flos rosae rugosae, 20-50 g of clove, 10-30 g of asarum, 20-50 g of raw pinellia ternate, 20-50 g of cinnamon, 5-20 g of scorpion, 10-20 g of borneol, 20-50 g of rhizoma arisaematis, 10-30 g of frankincense, 10-30 g of myrrh, 10-30 g of rheum officinale, 10-30 g of zedoary, 10-30 g of radix angelicae, 10-30 g of ferula asafoetida, 10-30 g of resurrection lily rhizome, 5-10 g of venenum bufonis, 0.1-0.5 g of muskone, 10-30 g of raw lumbricus, 2-5 g of tetracaine ointment and 5-10 g of diclofenac ointment. The flos rosae rugosae analgesic balm is simple in preparation method, effective in external treatment on cancer pain, capable of improving analgesic effect, definite in curative effect, and capable of reducing the usage amounts of bucinnazine and morphine, reducing the adverse reactions of Western medicines such as morphine, and improving the survival quality of patients.

The invention discloses a multifunctional composite sponge with effects of easing pain, stopping bleeding, disinfecting and sterilizing. The multifunctional composite sponge is mainly composed of a sponge matrix material and a local anesthetic, wherein the sponge matrix material is chitosan/polyethylene glycol modified three-dimensional porous gel; the local anesthetic is tetracaine hydrochlorideentrapped by a bletilla striata polysaccharide amphiphilic polymer shell. The multifunctional composite sponge is prepared by the following steps: taking the sponge matrix material as a drug-loading substrate, taking the local anesthetic as a loaded drug, and loading according to a weight part ratio of (4-9):(91-96). The sponge has multiple composite functions of stably easing pain and stopping bleeding in a long-acting manner as well as sterilizing and disinfecting, is excellent in biocompatibility, safe and convenient to use and high in comfort, and is a multifunctional composite sponge withhigh medical value and practical value.